Parvovirus B19

Revision as of 10:59, 24 July 2016 by Neil.m.young (talk | contribs) (Text replacement - "==Diagnosis==" to "==Evaluation==")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Background

  • In children: causes Erythema infectiosum (Fifth disease)
  • In transplant patients on immunosuppressive drugs: causes RBC aplasia.
    • Short-lived, may not be discovered
    • Parvovirus only replicated in erythroid progenitor cells

Clinical Features

Differential Diagnosis

Evaluation

  • Diagnosis is clinical usually through clinical presentation
  • IgM testing is recommended for immunocompromised patients.

Management

  • Parvovirus is usually self-limiting and requires no further treatment.
  • Management should be targeted at reducing symptoms, such as using anti-inflammatory medications for arthropathy or performing transfusions for aplastic anemia.

Disposition

See Also

External Links

References

  • Fish RM, Massad MG. The Transplant Patient. In: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Cydulka RK, Meckler GD, T. eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. New York, NY: McGraw-Hill; 2011.
  • Place R, Lagoc AT, Mayer TA, Lawlor CJ. Oncology and Hematology Emergencies in Children. In: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Cydulka RK, Meckler GD, T. eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. New York, NY: McGraw-Hill; 2011